Johnson & Johnson on Tuesday lifted its 2025 revenue guidance after posting stronger-than-expected third-quarter earnings and revealed plans to spin off its orthopedics business into a standalone company, its second major separation in two years. The New Jersey-based healthcare conglomerate said it now expects product revenue between $93.5 billion and $93.9 billion, up roughly $300











